Mifamurtide injection--Precautions when using Mepact

Mifamurtide injection (Mifamurtide), trade name Mepact, is an adjuvant treatment drug for specific types of osteosarcoma. It is suitable for the adjuvant treatment of high-grade, resectable, non-metastatic osteosarcoma in children, adolescents and young adults (age less than 30 years old) after complete gross surgical resection. When using Mepact, there are many important precautions that patients and medical staff need to understand and follow.

In terms of indications, it should be clearMepact is administered as adjuvant therapy after resection and must be used in conjunction with postoperative multi-drug chemotherapy and cannot be used alone. The recommended dose is 2mg/m2 body surface area, via intravenous injection, continuously 1 hour, 2 times a week, with an interval of at least 3 days, continuous administration12 weeks; after that, 1 time per week for 24 weeks, with a total treatment course of 36 weeks and 48 administrations.

When usingMepact, pay special attention to the patient's breathing. Bronchodilators should be considered on a prophylactic basis in patients with a history of asthma or other chronic obstructive pulmonary disease. During treatment, if mild to moderate respiratory distress related to treatment occurs, close observation is required; if severe respiratory reaction occurs, treatment should be stopped immediately and rescue treatment should be started.

Mepact may cause adverse reactions such as fever or chills. Body temperature changes should be closely monitored during treatment. At the same time, since the drug has a moderate impact on the ability to drive and use machinery, patients should avoid driving and operating machinery if they experience common adverse reactions such as dizziness, vertigo, fatigue, and blurred vision during treatment.

In terms of use by special groups, due to lack of relevant data, it is not recommended for pregnant women and children under 2 years of age. For lactating women, since it is unclear whether the drug is secreted in breast milk, it is necessary to fully evaluate the benefits of breastfeeding to the baby and the benefits of drug treatment to the mother before deciding whether to continue or stop breastfeeding.

In short, when using Mepact, patients and medical staff must strictly follow the doctor's instructions and pay close attention to the body's reaction to ensure the safety and effectiveness of the treatment.

Reference link: https://www.ema.europa.eu/en/documents/product-information/mepact-epar-product-information_en.pdf